Data / Drug companies / Glenmark Therapeutics Inc., USA
Glenmark Therapeutics Inc., USA: 23 products in the FDA NDC directory, labeler code 72657
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Glenmark Therapeutics Inc., USA (labeler code 72657) lists 23 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 23 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 1, 2026.
The request: Watch Glenmark Therapeutics Inc., USA (FDA labeler code 72657): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72657
- Products in commercial distribution
- 23
- Packages
- 77
- Finished drugs by generic name
- 12
- Prescription products
- 0
- Over the counter products
- 23
- Flagged as original packager
- 19 of 19 products that carry the flag
- Started marketing in the last 12 months
- 6
- Earliest marketing start
- June 1, 2022
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 19 | 82.6% |
| Over the counter monograph drugs | 4 | 17.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 23 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Cetirizine | 4 | 5 |
| Famotidine | 3 | 138 |
| Simethicone | 3 | 86 |
| Fluticasone propionate | 2 | 71 |
| Esomeprazole magnesium | 2 | 77 |
| Levonorgestrel | 2 | 31 |
| Adapalene | 2 | 34 |
| Olopatadine hydrochloride ophthalmic | 1 | 16 |
| Acetaminophen, ibuprofen | 1 | 23 |
| Olopatadine hydrochloride | 1 | 35 |
| Polyethylene glycol 3350 | 1 | 67 |
| Dextromethorphan hydrobromide | 1 | 17 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 4 | 17.4% |
| Tablet | 4 | 17.4% |
| Capsule, liquid filled | 4 | 17.4% |
| Spray, metered | 2 | 8.7% |
| Capsule, delayed release | 2 | 8.7% |
| Solution | 2 | 8.7% |
| Gel | 2 | 8.7% |
| Kit | 2 | 8.7% |
| Powder, for solution | 1 | 4.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Gas relief | 72657-482 | Capsule, liquid filled | Over the counter monograph drugs | November 1, 2026 |
| Gas relief | 72657-481 | Capsule, liquid filled | Over the counter monograph drugs | November 1, 2026 |
| Gas relief | 72657-480 | Capsule, liquid filled | Over the counter monograph drugs | November 1, 2026 |
| Dextromethorphan Hydrobromide | 72657-484 | Capsule, liquid filled | Over the counter monograph drugs | October 1, 2026 |
| Childrens Fluticasone Propionate ALLERGY RELIEF | 72657-166 | Spray, metered | Generic drugs (ANDA) | June 30, 2026 |
| Fluticasone Propionate ALLERGY RELIEF | 72657-159 | Spray, metered | Generic drugs (ANDA) | March 16, 2026 |
| Olopatadine hydrochloride | 72657-194 | Solution | Generic drugs (ANDA) | February 28, 2025 |
| Famotidine | 72657-132 | Tablet, film coated | Generic drugs (ANDA) | October 8, 2024 |
| Polyethylene Glycol 3350 | 72657-196 | Powder, for solution | Generic drugs (ANDA) | September 19, 2024 |
| Olopatadine hydrochloride | 72657-168 | Solution | Generic drugs (ANDA) | July 26, 2024 |
| Cetirizine HCl | 72657-131 | Kit | Generic drugs (ANDA) | May 13, 2024 |
| Cetirizine HCl | 72657-130 | Kit | Generic drugs (ANDA) | May 13, 2024 |
| Cetirizine HCl | 72657-129 | Tablet | Generic drugs (ANDA) | May 13, 2024 |
| Cetirizine HCl | 72657-128 | Tablet | Generic drugs (ANDA) | May 13, 2024 |
| Acetaminophen, Ibuprofen | 72657-157 | Tablet, film coated | Generic drugs (ANDA) | May 7, 2024 |
| Esomeprazole magnesium | 72657-127 | Capsule, delayed release | Generic drugs (ANDA) | August 22, 2023 |
| Esomeprazole magnesium | 72657-124 | Capsule, delayed release | Generic drugs (ANDA) | August 22, 2023 |
| Adapalene | 72657-158 | Gel | Generic drugs (ANDA) | March 10, 2023 |
| Adapalene | 72657-158 | Gel | Generic drugs (ANDA) | March 10, 2023 |
| Levonorgestrel | 72657-123 | Tablet | Generic drugs (ANDA) | February 9, 2023 |
| SheWise | 72657-108 | Tablet | Generic drugs (ANDA) | July 29, 2022 |
| Famotidine | 72657-113 | Tablet, film coated | Generic drugs (ANDA) | June 1, 2022 |
| Famotidine | 72657-112 | Tablet, film coated | Generic drugs (ANDA) | June 1, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.